Pulsenmore Ltd Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $12.5M0.0% YoYTTM through 31 Dec 2025
Net Income -$5MTTM through 31 Dec 2025
Free Cash Flow -$10.3MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Net Margin | -39.6% |
Returns
-19.1%ROE
-15.6%ROA
Balance Sheet Health
Current Ratio7.88x
Cash & Equivalents$6.8M
Quality Metrics
FCF Margin-82.5%
Multi-Year Trend
RevenueFY2025: $40M
Diluted EPSFY2025: $2.46
Dividend
No dividend
Capital Allocation
Capex Intensity0.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Portable Ultrasound Technologies | $12.5M | +374.0% | View detailsAims to accelerate commercial momentum and expand its presence in remote prenatal diagnostics in 2026 following FDA clearance for remote-use prenatal ultrasound in the U.S. and CE certification in Europe. |
Financials converted at 3.1760 from ILS.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.